* Deal values cancer drug developer Nuvalent at $124 per share * That is a 40% premium to the US-listed firm's close on Monday * GSK CEO Miels says deals expands lung cancer treatments * Deal size a
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)